Role of PELP1/MNAR signaling in ovarian tumorigenesis

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4902-4909

  Dimple, Chakravarty ^a   Nair, Sujit S ^a   Rajhans, Rajib ^a   Pitcheswara, Perla R ^a   Liu, Jinsong ^b   Balasenthil, Seetharaman ^b   Le, Xiao Feng ^b   Burow, Matthew E ^c   Auersperg, Nelly ^d   Tekmal, Rajeshwar Rao ^a   Broaddus, Russell R ^b   Vadlamudi, Ratna K ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TULANE UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; PROTEIN PELP1; SHORT HAIRPIN RNA; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; PELP1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; ONCOGENE SRC; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CELL ADHESION; CELL CULTURE; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG ANTAGONISM; ENDOMETRIOID CARCINOMA; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TISSUE MICROARRAY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANIMALS; CARCINOMA, ENDOMETRIOID; CELL ADHESION; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 49649094092     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5698     Document Type: Article

References (50)

1. Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer biology. Semin Oncol 1991;18:186-204.
2. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329:1550-9.
4. Collingwood TN, Urnov FD, Wolffe AP. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 1999;23:255-75.
5. Vadlamudi RK, Manavathi B, Balasenthil S, et al. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 2005;65: 7724-32.
6. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003;4:46-56.
7. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19:833-42.
8. Woenckhaus J, Franke FE, Hackethal A, Von GR, Munstedt K. Glucocorticosteroid receptors in ovarian carcinomas. Oncol Rep 2006;15:1137-40.
9. Wang PH, Chang C. Androgens and ovarian cancers. Eur J Gynaecol Oncol 2004;25:157-63.
10. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {β}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007;193:421-33.
11. Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol 2007;104:301-4.
12. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004;94:25-32.
13. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
14. Lonard DM, O'Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell 2006;125:411-4.
15. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20:1405-28.
16. O'Malley BW. Coregulators: from whence came these "master genes". Mol Endocrinol 2007;21:1009-13.
17. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
18. Quezada S, Avellaira C, Johnson MC, Gabler F, Fuentes A, Vega M. Evaluation of steroid receptors, coregulators, and molecules associated with uterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome. Fertil Steril 2006;85:1017-26.
19. Hussein-Fikret S, Fuller PJ. Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours. Mol Cell Endocrinol 2005;229:149-60.
20. Vadlamudi RK, Wang RA, Mazumdar A, et al. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor α. J Biol Chem 2001;276:38272-9.
21. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A 2002; 99:14783-8.
22. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004;64:6416-23.
23. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 2004;18:1096-108.
24. Balasenthil S, Vadlamudi RK. Functional interactions between the estrogen receptor coactivator PELP1/ MNAR and retinoblastoma protein. J Biol Chem 2003; 278:22119-27.
25. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/ MNAR. Nucl Recept Signal 2007;5:e004.
26. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 2005;65:5571-7.
27. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RRVR. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/Modulator of the nongenomic actions of the estrogen receptor. Cancer Res 2007;67:5505-12.
28. Salvo VA, Boue SM, Fonseca JP, et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 2006;12:7159-64.
29. Choi KC, Auersperg N, Leung PC. Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2001;86:5075-8.
30. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/ modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 2004; 89:6130-8.
31. Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ERh expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol 2005;36: 670-5.
32. Hammond SM, Caudy AA, Hannon GJ. Posttranscriptional gene silencing by double-stranded RNA. Nat Rev Genet 2001;2:110-9.
33. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNAin human cells. Nat Biotechnol 2002;20:505-8.
34. Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992;167:729-35.
35. Barnes CJ, Vadlamudi RK, Kumar R. Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 2004;61:281-91.
36. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005;5:343-57.
37. O'Malley BW. Molecular biology. Little molecules with big goals. Science 2006;313:1749-50.
38. Li AJ, Lerner DL, Gapuzan ME, Karlan BY. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomarkers Prev 2005;14: 2919-22.
39. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 2004;131:3469-79.
40. Bagheri-Yarmand R, Balasenthil S, Gururaj AE, et al. Metastasis- associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas. Cancer Res 2007;67:7062-7.
41. Nakayama K, Nakayama N, Jinawath N, et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-7.
42. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA, phosphorylated AKT. expression in ovarian cancer. Virchows Arch 2007;450:387-95.
43. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 2006;18:2262-71.
44. Torres-Arzayus MI, Font de MJ, Yuan J, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74.
45. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70S6K-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999;19:1346-58.
46. Liang J, Slingerland JM. Multiple roles of the PI3K/ PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
47. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
48. Greger JG, Fursov N, Cooch N, et al. Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol Cell Biol 2007;27:1904-13.
49. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004;5:575-85.
50. Nair S, Seetharaman B, Mueller JMKS, Schule R, Kumar R, Vadlamudi RK. PELP1/MNAR modulates LIM-only coactivator FHL2 transactivation functions. Mol Endocrinol 2007;21:613-24.